N/A
N=108
Mhealth for PrEP Adherence by Young Adult MSM, Phase 2
Hiv
Bottom Line
View on ClinicalTrials.gov: NCT04633200 ↗Enrolled (actual)
108
Serious AEs
0.0%
Results posted
Dec 2023
Primary outcome: Primary: Wilson Self-reported Medication Adherence Scale — 77.48; 71.59 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- DOT mobile app (Other)
- Age
- Adult · 18+ yrs
- Sex
- Male
- Sponsor
- Environment and Health Group, Inc.
- Primary completion
- Jun 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Wilson Self-reported Medication Adherence Scale |
77.48; 71.59 | — |
| SECONDARY PrEP Medication Adherence Self Efficacy Scale |
8.26; 7.63 | — |
| SECONDARY Intention to Follow PrEP Treatment Guidelines |
4.26; 3.93 | — |
| SECONDARY PrEP Medication Knowledge Measure |
6.75; 6.92 | — |
| SECONDARY Perceived Stress Scale |
2.19; 2.28 | — |
Summary
This Phase 2 project aims to enhance and test a mobile health intervention designed to increase adherence to the daily PrEP pill among culturally-diverse young adult men who have sex with men. The intervention will include: a) personalized PrEP pill reminders b) culturally- and developmentally-sensitive text messages targeting patient education, motivation, and stress c) a gamification avatar and d) a linked online community of peers. Effectively promoting PrEP adherence would reduce new HIV infections in this at-risk population, which is subject to health disparities
Eligibility Criteria
Inclusion Criteria: (self report) Individuals who self-identify as a male, age 18-35, who has sex with men or who self-identify as a bisexual male or a gay male; currently taking PrEP; own a smartphone and desirous of adherence support.
-
Exclusion Criteria: (self report) Males who do not meet the above criteria and/or currently use I.V. drugs.
Data sourced from ClinicalTrials.gov (NCT04633200). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.